View ValuationCoiled Therapeutics 将来の成長Future 基準チェック /06現在、 Coiled Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長24.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 28Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026. Location: the offices of reynolds porter chamberlain llp, tower bridge house, st katherines way, e1w 1aa, london United Kingdomお知らせ • Apr 10Coiled Therapeutics plc Provides Clinical Trial Update on AO-252Coiled Therapeutics plc provided an update on its clinical trial (NCT06136884) evaluating AO-252, a first-in-class TACC3 inhibitor. The transition to a Twice-Daily ("BID") dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate ("CBR"), a significant improvement over the 40% CBR observed in the Once-Daily ("QD") cohort. A particularly notable result has been observed in a leiomyosarcoma patient, who achieved Stable Disease after just two cycles of AO-252, despite having received nine prior lines of therapy. 80% of evaluable patients in the BID cohort achieved tumour stabilisation or regression, with treatment durations exceeding six months. This substantially outperforms the two to three month benchmark typically seen with salvage therapy in this heavily pre-treated population. AO-252 continues to demonstrate excellent tolerability with no serious adverse events observed to date. The Maximum Tolerated Dose ("MTD") has not yet been reached, allowing for continued dose escalation to optimise therapeutic impact. Following encouraging signals, the Company is accelerating the transition to targeted dose expansion cohorts in ovarian and prostate cancers, with an enrolment target of 40 patients by Third Quarter 2026. Emerging data confirms AO-252's unique dual-action profile, combining direct cytotoxicity with immune-system activation via the cGAS/STING pathway. On track to complete dose escalation in First Half 2026, with a next-generation formulation to optimise dosing/efficacy and combination therapy protocols scheduled for mid-2026. The ongoing Phase I/II open-label dose escalation study of AO-252 in patients with advanced solid tumours has enrolled 31 patients to date, of whom 25 are evaluable for safety and dose-limiting toxicity ("DLT") assessment and 21 are evaluable for efficacy. Dose escalation remains on track for completion in First Half 2026. The transition to a BID dosing regimen in Cohort 4b has produced a clinically meaningful step-change in disease control. An 80% CBR has been observed in Cohort 4b, compared to 40% in the QD Cohort 4a, reflecting the importance of sustained drug exposure at therapeutic levels. Four out of five evaluable patients in Cohort 4b demonstrated tumour stabilisation or regression. Notably, treatment duration in this cohort has exceeded six months, substantially longer than the two to three months typically achieved with salvage therapy in these heavily pretreated populations (median of five prior lines of therapy). AO-252 appears to possess meaningful immune-modulatory activity, consistent with its known ability to stimulate the cGAS/STING pathway and activate dendritic cells and M1 macrophages. This positions AO-252 as a potentially rare small molecule capable of directly activating the immune system in addition to its direct anti-tumour cytotoxic effects. The Company believes this immune-modulatory property could significantly enhance AO-252's utility in combination regimens, including with immuno-oncology agents, and broadens its differentiated therapeutic profile and commercial appeal. Analysis of clinical pharmacokinetic data has identified distinct drug exposure variances between male and female patients. This finding is being incorporated into refined dose modelling to ensure optimal efficacy and safety parameters as the programme advances. A dedicated sub-arm of Cohort 4b is currently evaluating the impact of food on AO-252 absorption, with efficacy and pharmacokinetic data expected in late Second Quarter 2026. In parallel, a next-generation formulation of AO-252 is on track for introduction in mid-2026. The refined formulation is designed to further improve drug exposure to attain maximal efficacy and duration of therapy. Leveraging AO-252's immune-modulatory backbone and its demonstrated synergy with immuno-oncology and antibody-drug conjugate agents in preclinical studies, the Company is actively developing a combination therapy protocol. Study initiation is targeted for Third Quarter 2026, with a view to exploring AO-252's potential in multi-agent oncology regimens. The Company is preparing to transition from the current broad dose escalation strategy to targeted dose expansion cohorts focused primarily on ovarian and prostate cancer indications where early clinical signals have been particularly encouraging and where commercial interest from large pharmaceutical companies is strong. The Company is targeting enrolment of 40 patients by Third Quarter 2026. Strategic engagement with Key Opinion Leaders (KOLs) continues to refine the clinical development strategy, ensuring that study design and patient selection remain aligned with the emerging scientific understanding of AO-252's unique mechanism of action. Key milestones for 2026 are summarised below: First Half 2026: Completion of Phase I dose escalation; preliminary proof-of-concept safety and efficacy data from dose escalation phase. Late Second Quarter 2026: Food-effect sub-arm data from Cohort 4b pharmacokinetic study. Mid-2026: Introduction of refined next-generation formulation of AO-252. Third Quarter 2026: Initiation of combination therapy protocol study; 40-patient enrolment target reached. Second Half 2026: Comprehensive expansion cohort efficacy and safety data readouts in ovarian and prostate cancer; potential Phase II registrational trial planning and commercial discussions. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Coiled Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:COTX.F - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数アナリストによる今後の成長予測収入対貯蓄率: COTX.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: COTX.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: COTX.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: COTX.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: COTX.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: COTX.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/07 17:40終値2026/06/02 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Coiled Therapeutics plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 28Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026. Location: the offices of reynolds porter chamberlain llp, tower bridge house, st katherines way, e1w 1aa, london United Kingdom
お知らせ • Apr 10Coiled Therapeutics plc Provides Clinical Trial Update on AO-252Coiled Therapeutics plc provided an update on its clinical trial (NCT06136884) evaluating AO-252, a first-in-class TACC3 inhibitor. The transition to a Twice-Daily ("BID") dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate ("CBR"), a significant improvement over the 40% CBR observed in the Once-Daily ("QD") cohort. A particularly notable result has been observed in a leiomyosarcoma patient, who achieved Stable Disease after just two cycles of AO-252, despite having received nine prior lines of therapy. 80% of evaluable patients in the BID cohort achieved tumour stabilisation or regression, with treatment durations exceeding six months. This substantially outperforms the two to three month benchmark typically seen with salvage therapy in this heavily pre-treated population. AO-252 continues to demonstrate excellent tolerability with no serious adverse events observed to date. The Maximum Tolerated Dose ("MTD") has not yet been reached, allowing for continued dose escalation to optimise therapeutic impact. Following encouraging signals, the Company is accelerating the transition to targeted dose expansion cohorts in ovarian and prostate cancers, with an enrolment target of 40 patients by Third Quarter 2026. Emerging data confirms AO-252's unique dual-action profile, combining direct cytotoxicity with immune-system activation via the cGAS/STING pathway. On track to complete dose escalation in First Half 2026, with a next-generation formulation to optimise dosing/efficacy and combination therapy protocols scheduled for mid-2026. The ongoing Phase I/II open-label dose escalation study of AO-252 in patients with advanced solid tumours has enrolled 31 patients to date, of whom 25 are evaluable for safety and dose-limiting toxicity ("DLT") assessment and 21 are evaluable for efficacy. Dose escalation remains on track for completion in First Half 2026. The transition to a BID dosing regimen in Cohort 4b has produced a clinically meaningful step-change in disease control. An 80% CBR has been observed in Cohort 4b, compared to 40% in the QD Cohort 4a, reflecting the importance of sustained drug exposure at therapeutic levels. Four out of five evaluable patients in Cohort 4b demonstrated tumour stabilisation or regression. Notably, treatment duration in this cohort has exceeded six months, substantially longer than the two to three months typically achieved with salvage therapy in these heavily pretreated populations (median of five prior lines of therapy). AO-252 appears to possess meaningful immune-modulatory activity, consistent with its known ability to stimulate the cGAS/STING pathway and activate dendritic cells and M1 macrophages. This positions AO-252 as a potentially rare small molecule capable of directly activating the immune system in addition to its direct anti-tumour cytotoxic effects. The Company believes this immune-modulatory property could significantly enhance AO-252's utility in combination regimens, including with immuno-oncology agents, and broadens its differentiated therapeutic profile and commercial appeal. Analysis of clinical pharmacokinetic data has identified distinct drug exposure variances between male and female patients. This finding is being incorporated into refined dose modelling to ensure optimal efficacy and safety parameters as the programme advances. A dedicated sub-arm of Cohort 4b is currently evaluating the impact of food on AO-252 absorption, with efficacy and pharmacokinetic data expected in late Second Quarter 2026. In parallel, a next-generation formulation of AO-252 is on track for introduction in mid-2026. The refined formulation is designed to further improve drug exposure to attain maximal efficacy and duration of therapy. Leveraging AO-252's immune-modulatory backbone and its demonstrated synergy with immuno-oncology and antibody-drug conjugate agents in preclinical studies, the Company is actively developing a combination therapy protocol. Study initiation is targeted for Third Quarter 2026, with a view to exploring AO-252's potential in multi-agent oncology regimens. The Company is preparing to transition from the current broad dose escalation strategy to targeted dose expansion cohorts focused primarily on ovarian and prostate cancer indications where early clinical signals have been particularly encouraging and where commercial interest from large pharmaceutical companies is strong. The Company is targeting enrolment of 40 patients by Third Quarter 2026. Strategic engagement with Key Opinion Leaders (KOLs) continues to refine the clinical development strategy, ensuring that study design and patient selection remain aligned with the emerging scientific understanding of AO-252's unique mechanism of action. Key milestones for 2026 are summarised below: First Half 2026: Completion of Phase I dose escalation; preliminary proof-of-concept safety and efficacy data from dose escalation phase. Late Second Quarter 2026: Food-effect sub-arm data from Cohort 4b pharmacokinetic study. Mid-2026: Introduction of refined next-generation formulation of AO-252. Third Quarter 2026: Initiation of combination therapy protocol study; 40-patient enrolment target reached. Second Half 2026: Comprehensive expansion cohort efficacy and safety data readouts in ovarian and prostate cancer; potential Phase II registrational trial planning and commercial discussions.